- Home
- RDI vs CGTX Comparison
RDI vs CGTX Comparison
Compare RDI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- CGTX
- Stock Information
- Founded
- RDI 1937
- CGTX 2007
- Country
- RDI United States
- CGTX United States
- Employees
- RDI N/A
- CGTX N/A
- Industry
- RDI Movies/Entertainment
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- CGTX Health Care
- Exchange
- RDI Nasdaq
- CGTX Nasdaq
- Market Cap
- RDI 35.2M
- CGTX 30.0M
- IPO Year
- RDI N/A
- CGTX 2021
- Fundamental
- Price
- RDI $1.40
- CGTX $0.58
- Analyst Decision
- RDI Hold
- CGTX Strong Buy
- Analyst Count
- RDI 1
- CGTX 6
- Target Price
- RDI $2.40
- CGTX $8.30
- AVG Volume (30 Days)
- RDI 71.0K
- CGTX 809.4K
- Earning Date
- RDI 03-31-2025
- CGTX 03-25-2025
- Dividend Yield
- RDI N/A
- CGTX N/A
- EPS Growth
- RDI N/A
- CGTX N/A
- EPS
- RDI N/A
- CGTX N/A
- Revenue
- RDI $197,270,000.00
- CGTX N/A
- Revenue This Year
- RDI N/A
- CGTX N/A
- Revenue Next Year
- RDI $18.29
- CGTX N/A
- P/E Ratio
- RDI N/A
- CGTX N/A
- Revenue Growth
- RDI N/A
- CGTX N/A
- 52 Week Low
- RDI $1.22
- CGTX $0.34
- 52 Week High
- RDI $1.97
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- RDI 38.79
- CGTX 40.43
- Support Level
- RDI $1.54
- CGTX $0.57
- Resistance Level
- RDI $1.62
- CGTX $0.65
- Average True Range (ATR)
- RDI 0.10
- CGTX 0.05
- MACD
- RDI -0.02
- CGTX -0.01
- Stochastic Oscillator
- RDI 11.63
- CGTX 9.46
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.